Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.

Additional locations may be listed on ClinicalTrials.gov for NCT04524455.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationAmgen, Inc.

• Primary ID20190177
• Secondary IDsNCI-2020-07630
• ClinicalTrials.gov IDNCT04524455